Several studies have shown that patients with less heterogeneous melanoma responded better to the blocking action of anti-CTLA-4 and anti-PD1, supporting the concept that the high heterogeneity implies a major presence of tumor subclones, able to bypass the immune system and thus drug resistance [136]. The gene discussed is PDCD1; the disease is melanoma.